Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2025)

Ascendis Pharma A (ASND) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $461.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 14.32% to $461.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $461.0 million through Dec 2025, up 14.32% year-over-year, with the annual reading at $461.0 million for FY2025, 14.32% up from the prior year.
  • Total Non-Current Liabilities hit $461.0 million in Q4 2025 for Ascendis Pharma A, up from $403.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $668.4 million in Q4 2022 to a low of $115.5 million in Q4 2021.
  • Historically, Total Non-Current Liabilities has averaged $380.1 million across 5 years, with a median of $403.2 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 478.88% in 2022 and later crashed 62.21% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $115.5 million in 2021, then soared by 478.88% to $668.4 million in 2022, then plummeted by 62.21% to $252.6 million in 2023, then soared by 59.63% to $403.2 million in 2024, then rose by 14.32% to $461.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ASND at $461.0 million in Q4 2025, $403.2 million in Q4 2024, and $252.6 million in Q4 2023.